The evolution in the use of MIBG in more than 25 years of experimental and clinical applications

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 341-350

  Rufini, V ^a,c   Shulkin, B ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

3 Iodobenzylguanidine; Neoplasms, radionuclide imaging; Neoplasms, therapy; Radiopharmaceuticals

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ASTATINE 211; TOPOTECAN;

ADRENERGIC NERVE; CARDIOTOXICITY; CLINICAL PRACTICE; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; DRUG USE; GEOGRAPHIC DISTRIBUTION; HEART DISEASE; HUMAN; INSTRUMENTATION; NEUROENDOCRINE TUMOR; NONHUMAN; PUBLICATION; RADIOCHEMISTRY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS; TUMOR SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ANIMALS; HUMANS; LITERATURE; NEUROENDOCRINE TUMORS; RADIOCHEMISTRY; TISSUE DISTRIBUTION;

EID: 60549086796     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. 131I-iodobenzylguanidine. J Nucl Med 1980;21:349-53.
2. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
3. 131I-metaiodobenzylguanidine. J Nud Med 1984;25:773-5.
4. 131I-MIBG. Lancet 1984;2:165.
5. 131I-MIBG. Lancet 1984;2:233.
6. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625-36.
7. Giordano A, Calcagni ML, Rossi B, Rufini V, Fuso L, Valente S et al. Use of metaiodobenzylguanidine (MIBG) in pneumology. Q J Nucl Med 1995;38(4 Suppl 1):49-54.
8. Giordano A, Calcagni ML, Rossi B, Fuso L, Accardo, D, Valente S et al. Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. Eur J Nucl Med 1997;24:52-8.
9. 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 2005;32:221-8.
10. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002;9:75-94.
11. Knuuti J, Sipola P. Is it time for cardiac innervation imaging? Q J Nucl Med Mol Imaging 2005;49:97-105.
12. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol 2008;15:442-55.
13. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;25:197-206.
14. 131I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995;31A:606-11.
15. 131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett 2005;228:221-7.
16. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
17. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26:539-46.
18. Smets LA, Loesberg L, Janssen M, Metwally EA, Huiskam R. Active uptake and extravesicular storage of metaiodobenzylguanidine in human SK-N-SH cells. Cancer Res 1989;49:2941-4.
19. Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of the neuron-blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990;39:1959-64.
20. Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H et al. Uptake of metaiodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters. Br J Cancer 2003;89:1383-8.
21. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
22. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
23. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
24. 124I-MIBG. J Nucl Med 2007;48:827-36.
25. Binderup T, Knigge U, Mogensen AM, Hasen CP, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008;87:223-32.
26. 131I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 2003;9:3338-44.
27. Cleary S, Phillips JK. The norepinephrine transporter and pheochromocytoma. Ann N Y Acad Sci 2006;1073:263-9.
28. Mairs RJ, Boyd M. Targeting radiotherapy to cancer by gene transfer. J Biomed Biotechnol 2003;2:102-9.
29. Cunningham S, Boyd M, Brown MM, Carlin S, McCluskey A, Livingstone A et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Ped Oncol 2000;35:708-11.
30. 131I]MIBG and clonogenic cell kill. Oncogene 2001;20:7804-8.
31. Fullerton NE, Boyd M, Mairs RJ, Keith WN, Alderwish O, Brown MM et al. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer Prostatic Dis 2004;7:355-63.
32. Fullerton NE, Mairs RJ, Kirk D, Keith WN, Carruthers R, McKluskey AG et al. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines. Eur Urol 2005;47:250-6.
33. Altmann A, Kissel M, Zitzmann S, Kübler W, Mahmut M, Peschke P et al. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 2003;44:973-80.
34. 131I-MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672-82.
35. Bonnin F, Lumbroso J, Tenebaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-10.
36. 123I-metaiodobenzylguanidine in the contralateral adrenal region after resection of an adrenal pheochromocytoma. N Engl J Med 2000;342:1450-1.
37. 123I-metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue. J Nucl Med 2003;44:1421-5.
38. 123I-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol 2004;34:577-9.
39. Sandler ED, Hattner RS, Parisi MT. Asymmetry of salivary gland I123 metaiodobenzylguanidine (MIBG) uptake in a patient with cervical neuroblastoma and Horner's syndrome. Possible etiologic mechanisms. Pediatr Radiol 1992;22:225-6.
40. 131I-iodobenzylguanidine (1-131-MIBG) and circulating catecholamines in suspected pheochromocytomas. J Nucl Med 1983;24:1127-34.
41. Morozumi T, Fukuchi K, Uehara T. Abnormal iodine-123-MIBG images in healthy volunteers. J Nucl Med 1996;37:1686-8.
42. Dwamena BA, Zempel S, Klopper JF, van Heerden B, Wieland D, Shapiro B. Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma. Clin Nucl Med 1998;23:441-5.
43. Roelants V, Goulios C, Beckers C, Jamar F. Iodine-131-MIBG scintigraphy in adults: interpretation revisited? J Nucl Med 1998;39:1007-12.
44. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals. Annals of ICRP. Oxford: Pergamon Press; 1998.
45. 123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:BP 132-9.
46. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 1986;11:851-4.
47. 123I-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine. Eur J Nucl Med 2000;27:611-2.
48. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med 2008;52:351-68.
49. 131I-meta-iodobenzylguanidine. Eur Nucl Med 1984;9:429-32.
50. Schillaci O. Functional anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharin 2004;19:129-34.
51. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med 2006;36:212-7.
52. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, Klein M. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-90.
53. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. 131-Iodine-metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985;26:576-85.
54. Troncone L, Rufini V, Montemaggi P, Danza FM, Lasorella A, Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylpanidine (MIBG): 5 years of experience. Eur J Nucl Med 1990;16:325-35.
55. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:3-8.
56. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217-23.
57. Troncone L, Rufini V. MIBG in diagnosis of neuroendocrine tumors. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. Vol 1. Edinburgh: Churchill Livingstone; 2004.p.83-95.
58. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
59. Leung A, Shapiro B, Hattner R, Kim E, d Kraker J, Ghazzar N et al. The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997;38:1352-7.
60. Havekes B, Lai EW, Corssmit PM, Romijn JA, Timmers HJLM, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008;52:419-29.
61. Boubaker A, Bishof-Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:388-402.
62. Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 2008;52:441-54.
63. Castellani MR, Seregni E, Maccauro, Chiesa C, Aliberti G, Orunesu E et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 2008; 52:430-40.
64. Cecchin D, Lumachi F, Marzola MC, Opocher G, Scaroni C, Zucchetta P et al. Meta-iodoenzylguanisine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancr 2006;13:525-33.
65. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000;34:237-41.
66. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91.
67. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high risk neuroblastoma. J Clin Oncol 2004;22:3909-15.
68. Kushner B, Cheung NK. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Ped Blood Cancer 2006;47: 863-4.
69. Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B et al. Evaluation of a semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Ped Blood Cancer 2006;45:865-74.
70. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Onc 1993;11:1466-77.
71. Olivier P, Colarinha P, Fettich J, Fischer S, Frökier J, Giammarile F et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45-50.
72. Franzius C, Schmidt M, Hero B, Pfluger T, Hahn K; Deutsche Gesellschaft für Nuklearmedizin (DGN); Neuroblastom-Studiengruppe der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). [Procedure guidelines for MIBG-scintigraphy in children]. Nuklearmedizin 2008;47:132-8.
73. 131I-MIBG in the treatment of neural crest tumor. Proceedings of an International Workshop. Rome, September 6-7. J Nucl Biol Med 1991;35:177-363.
74. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 1999;43:336-43.
75. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344-55.
76. Mitjavila M. Meta-iodobenzylguanidine in neuroblastoma: from diagnosis to therapy. Nucl Med Commun 2002;23:3-4.
77. Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308-14.
78. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 1994;15:746-51.
79. Mastrangelo R, Lasorella A, Iavarone A, Rufini V, Troncone L, Danza F et al. Clinical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med Pediatr Oncol 1993;21:411-5.
80. Meller S. Targeted radiotherapy for neuroblastoma. Arch Dis Child 1997;77:389-91.
81. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-9.
82. 131I]meta-iodobenzylguanidine and topotecan in combination. Br J Radiol 2008;81 Spec No 1:S28-35.
83. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refratory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol 2006;24:500-6.
84. Taggart D, Dubois S, Matthay KK. Radiolabelled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
85. Matthay KK, Panina C, Huberty, Price D, Glidden DV, Tang HR et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713-21.
86. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47:3211-23.
87. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiother 2003;18:81-7.
88. 131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008; 35:1039-47.
89. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308-16.
90. 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 2007;22:105-12.
91. 131I-meta-iodobenzylguanidine therapy. Eur J Nucl Med Mol Imaging 2003;30:BP23-6.
92. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.
93. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B et al. Myocardial imaging in man with I-123-meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.
94. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI et al. Underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.
95. Mushtaq N, Gerson MC. I-123 metaiodobenzylguanidine imaging in non-insulin-dependent diabetic patients with normal myocardial perfusion scans: new insights into their increased cardiac morbidity and mortality rates. J Nucl Cardiol 2006; 13:8-10.
96. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
97. Estorch M. From the heart to the brain via cardiac MIBG imaging. Eur J Nucl Med Mol Imaging 2006;33:246-7.
98. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
99. Camacho V, Carrió I. Targeting neuronal dysfunction and receptor imaging. Curr Opin Biotechnol 2007;18:60-4.
100. Bax JJ, Boorgers M, Henneman MM. Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients? Eur J Nucl Med Mol Imaging 2008;35:532-4.
101. 123I-mIBG scintigraphy in heart failure. Q J Nucl Med Mol Imaging 2008;52: 369-77.
102. Yamashima, S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:S62-S73.
103. Lucignani G. Cardiac sympathetic denervation imaging in movement disorders and dementias. Eur J Nucl Med Mol Imaging 2008;35:681-5.
104. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008;52:378-87.
105. Japanese Circulation Society Joint Working Groups for Guidelines for Diagnosis and Treatment of Cardiovascular Diseases. Guidelines of clinical use of cardiac nuclear medicine (JCS205). J Cardiol 2006;48:405-9.